Search clinical trials for: BMS-986408

Total 3156 results

Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Healthy Volunteers

United States
Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Imperial College Healthcare NHS Trust
Imperial College London; University of Oxford; Oxford University Hospitals NHS...

Withdrawn

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations (SABRE)

Lymphoma | Leukemia | Immune Thrombocytopenia | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | Myeloma | Thrombotic Thrombocytopenic Purpura (TTP)

United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Taiwan, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Peru, Poland, Portugal, Spain, Switzerla... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Pulmonary Fibrosis

Canada, France, United States, Argentina, Australia, Belgium, Brazil, Chile, China, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Healthy Volunteers

United States
Hoffmann-La Roche

Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Healthy Adults

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Biogen

Completed

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Tauopathies

United States
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Bristol-Myers Squibb

Not yet recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
Celgene

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Phase 1 Study of Mesothelin-ADC

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Healthy Volunteers

China
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Biogen

Terminated

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Supranuclear Palsy, Progressive

United States
Bristol-Myers Squibb

Withdrawn

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Available

Expanded Access for Repotrectinib
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

United States, Australia, Canada, France, Germany, Ireland, Italy, Spain, United Kingdom
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Renal Impairment

United States
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
MedSIR
Medical University of Vienna

Not yet recruiting

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE)

NSCLC | Brain Metastases | ROS1 Gene Rearrangement
Celgene

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Healthy Volunteers

United States
Celgene

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

Healthy Volunteers

Belgium
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
Bristol-Myers Squibb

Completed

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
Bristol-Myers Squibb

Not yet recruiting

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Hepatic Impairment | Healthy Participants
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
Bristol-Myers Squibb

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

Alzheimer Disease, Early Onset

United States, Australia, Belgium, Canada, France, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, United Kingdom, Denmark, Germany, Italy, Poland
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Healthy Volunteers

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
M.D. Anderson Cancer Center

Active, not recruiting

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Malignant... and other conditions

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand

Search clinical trials for: BMS-986408

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations